Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

Emile Verhulst, Delphine Garnier, Ingrid De Meester, Brigitte Bauvois

Open source

DOI
10.3390/cancers14030624
Published
2022-01-26
Container
Cancers
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers14030624,
  title = {Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?},
  author = {Emile Verhulst and Delphine Garnier and Ingrid De Meester and Brigitte Bauvois},
  year = {2022},
  journal = {Cancers},
  doi = {10.3390/cancers14030624},
  url = {https://doi.org/10.3390/cancers14030624}
}

RIS

TY  - JOUR
TI  - Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?
AU  - Emile Verhulst
AU  - Delphine Garnier
AU  - Ingrid De Meester
AU  - Brigitte Bauvois
PY  - 2022
JO  - Cancers
DO  - 10.3390/cancers14030624
UR  - https://doi.org/10.3390/cancers14030624
ER  - 

APA

Verhulst, E., Garnier, D., Meester, I. D., & Bauvois, B. (2022). Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?. Cancers. https://doi.org/10.3390/cancers14030624

Source records